Raasi

Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Retrieved on: 
星期三, 七月 6, 2022
Kidney failure, ARB, Diagnosis, IgA nephropathy, Patient, ESRD, Polyomaviridae, Research, Dialysis, HIV disease progression rates, GLOBE, Biomarker, COVID-19, BK virus, EGFR, TACI, Union, Disease, Virus, U.S. Securities and Exchange Commission, UPCR, Autoantibody, Chronic kidney disease, Cytokine, Stanford University School of Medicine, Immunoglobulin A, Data analysis, Inflammation, Degenerative disease, Kidney, B cell, Immunoglobulin G, Serum, Security (finance), Raasi, Private Securities Litigation Reform Act, FACP, Standard of care, Glomerular filtration rate, Proteinuria, Nasdaq, Lupus nephritis, BK, Autoimmune disease, Coagulation, Acei, Safety, B-cell activating factor, Therapy, Pharmaceutical industry, Vaccine

This builds on the already compelling disease-modifying dose-dependent activity and well-tolerated safety profile for atacicept.

Key Points: 
  • This builds on the already compelling disease-modifying dose-dependent activity and well-tolerated safety profile for atacicept.
  • We look forward to the results of the ORIGIN trial which will be a first for the field.
  • Subjects were randomized 2:2:1:2 to atacicept 150 mg, atacicept 75 mg, atacicept 25 mg, or matching placebo.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study.

DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy

Retrieved on: 
星期一, 四月 4, 2022
Health, Other Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Chronic kidney disease, Risk, Nephrology, ACC, SIX Swiss Exchange, LR, Dialysis, Raasi, Marketing, HF, Fresenius Medical Care, Vifor Pharma, Guideline, ISIN, Health, Hyperkalemia, American College, COVID-19, ART, Potassium, Executive Committee, Iron, Heart failure, Patient, Pharmaceutical industry, VIFOR PHARMA GROUP, THE DIAMOND TRIAL

53 LR

Key Points: 
  • 53 LR
    Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa allowed patients to achieve long-term potassium control, reduced the risk of recurrent hyperkalemia and prolonged optimized and guideline recommended renin-angiotensin aldosterone system inhibitor (RAASi) therapy.
  • For cases where hyperkalemia is the dominant reason for not giving guideline-directed RAASi therapy, Veltassa can be an enablement strategy to allow patients to get optimized RAASi therapy while simultaneously lowering the risk of hyperkalemia.
  • To date, Veltassa is the only potassium binder studied in placebo-controlled trials proven to control potassium without compromising RAASi in a variety of patient profiles.
  • DIAMOND is the largest interventional study for potassium binders assessing control of serum potassium, hyperkalemia events, and enablement of RAASi in heart failure patients with reduced ejection fraction and hyperkalemia in more than 1,000 patients.

Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®

Retrieved on: 
星期二, 十二月 21, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Raasi, Cardiology, LR, Vifor Pharma, Hyperkalemia, ISIN, ART, Fresenius Medical Care, Heart failure, Conditional sentence, Guideline, COVID-19, History, Risk, SIX Swiss Exchange, Nephrology, HF, Chronic kidney disease, Executive Committee, Patient, Health, Pharmaceutical industry

Vifor Pharma expects the key trial results to be presented at a major cardiology conference in H1 2022.

Key Points: 
  • Vifor Pharma expects the key trial results to be presented at a major cardiology conference in H1 2022.
  • We are delighted and very encouraged about the positive read-out from the DIAMOND trial for the heart failure patient community, said Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma.
  • Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines

Retrieved on: 
星期二, 八月 31, 2021
Biotechnology, Pharmaceutical, Health, Cardiology, HF, European Society of Cardiology, Fresenius Medical Care, Nephrology, The I.V. Stalin White Sea – Baltic Sea Canal, Quality of life, SIX Swiss Exchange, Calcium, Iron, Diagnosis, Iron deficiency, Raasi, Conditional sentence, Physician, Sodium, Vifor Pharma, FCM, Emergency, Heart, Hyperkalemia, Health, Mortality, Safety, Risk, ISIN, ESC, Patient, Class, Degenerative disease, RAAS, Meta-analysis, Pharma, Heart failure, Medical device, Pharmaceutical industry

Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure for two of their key products, Ferinject and Veltassa.

Key Points: 
  • Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure for two of their key products, Ferinject and Veltassa.
  • The guidelines also propose that the use of potassium binder agents like Veltassa may allow RAAS inhibitor initiation or uptitration in a larger proportion of heart failure patients.
  • Reducing the risk of heart failure hospitalizations and improving symptoms are key therapeutic goals in the treatment of heart failure.
  • The ESC HF guidelines are updated periodically, with the 2021 version published at the virtual ESC congress end of August 2021.

Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1

Retrieved on: 
星期四, 八月 5, 2021
Biotechnology, Pharmaceutical, Health, Iron-deficiency anemia, Growth, United States dollar, Manuscript, ANCA, Board, Annual, Marketing, Scd, Income, Hospital, Kidney, Blood, Earnings before interest, taxes, depreciation and amortization, Erythropoiesis-stimulating agent, Review, European Medicines Agency, EMA, Cer, Food and Drug Administration, The New England Journal of Medicine, Sickle cell disease, Therapy, Group, CKD, Anemia, Population, Iron, Mortality, Advisory Committee, European Heart Journal, Depreciation, Dialysis, Raasi, Vifor Pharma, File, Quality of life, Leadership, Hyperkalemia, Awareness, European Space Agency, Pharma, Heart failure, Prescription Drug User Fee Act, Adoption, Annual general meeting, Maa, Executive Committee, Patient, COVID-19, PBM, CHF, NDA, Director, Overalls, Heart, Pharmaceutical industry, Medical device, Aquaculture

Based on the solid results in H1 2021, the Group is confident of achieving its full year guidance.

Key Points: 
  • Based on the solid results in H1 2021, the Group is confident of achieving its full year guidance.
  • Ferinject / Injectafer net sales increased 22.4% (up 22.8% at CER) to CHF 320.5 million in H1 2021 from CHF 261.9 million a year earlier.
  • As a result, Vifor Pharma posted net sales of CHF 73.7 million, up 1.4% or 8.5% at CER.
  • Abbas Hussain was appointed Chief Executive Officer of Vifor Pharma, succeeding Stefan Schulze, who has decided to step down for personal reasons.